Skip to main content
SpringerLink
Log in

Renin Inhibitors: Cardiovascular drugs of the future?

Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

Summary

This review explores whether the therapeutic attractiveness of renin inhibitors compared with angiotensinconverting enzyme (ACE) inhibitors and angiotensin II receptor antagonists, is sufficient to warrant continued interest in their development for the treatment of cardiovascular discase. Clinical and experimental data available to date indicate that patients with hypertension and congestive heart failure will benefit from renin inhibition. However, clinical experience is very limited, and extra benefits of renin inhibitors compared with the other blockers of the reninangiotensin system (RAS) have yet to be demonstrated. Some experimental data in animals and humans point to a greater effect of acute renin inhibition on renal blood flow than other modes of interference with the RAS. Again, the clinical benefits of such an effect, and particularly after long-term treatment, in hypertension and renal disease need to be determined. In today's cost-conscious health setting, only new drugs that bring additional clinical benefits have a good chance of being commercially viable. It remains to be seen whether renin inhibitors will fulfill these criteria.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

References

  1. GavrasI. Bradykinin-medicated effects of ACE inhibition.Kidney Int 1992;42:1020–1029.

    PubMed  CAS  Google Scholar 

  2. TimmermansPBMWM, CariniDJ, ChiuAT, HerblinWF. Angiotensin II receptor antagonists: From discovery to antihypertensive drugs.Hypertension 1991;18(Suppl 3):136–142.

    Google Scholar 

  3. CriscioneL, deGasparoM, BühlmayerP, WhitebreadS, RamjouéHPJ, WoodJM. Pharmacological profile of valsartan: A potent, orally active, nonpeptide antagonist of the angiotensin II AT-receptor subtype.Br J Pharmacol 1993; 110:761–771.

    PubMed  CAS  Google Scholar 

  4. KleinertHD. Renin inhibition.Cardiovasc Drugs Ther 1995;9:645–655.

    Article  PubMed  CAS  Google Scholar 

  5. WoodJM, CuminF, MaibaumJ. Pharmacology of renin inhibitors and their application to the treatment of hypertension.Pharm Ther 1994;61:325–344.

    Article  CAS  Google Scholar 

  6. FerrarioCM, ChappellMC. A hew myocardial conversion of angiotensin 1.Curr Opin Cardiol 1994;9:520–526.

    Article  PubMed  CAS  Google Scholar 

  7. NussbergerJ, BrunnerDB, WaeberB, BrunnerHR. True versus immunoreactive angiotensin II in human plasma.Hypertension 1985;7(Suppl 1):1–7.

    CAS  Google Scholar 

  8. AziziM, ChatellierG, GuyeneTT, Murieta-GeoffroyD, MénardJ. Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives.Circulation 1995;92:825–834.

    PubMed  CAS  Google Scholar 

  9. FossaAA, WeinbergLJ, BarberRL, et al. Synergistic effect on reduction in blood pressure with coadministration of the renin inhibitor, CP-80,794, and the angiotensin converting enzyme inhibitor, captopril.J Cardiovasc Pharmacol 1992;20:75–82.

    Article  PubMed  CAS  Google Scholar 

  10. FossaAA, DePasqualeMJ, RingerLJ, WinslowRL. Synergistic effect on reduction in blood pressure with coadministration of a renin inhibitor or an angiotensin-converting enzyme inhibitor with an angiotensin II receptor antagonist.Drug Dev Res 1994;33:422–428.

    Article  CAS  Google Scholar 

  11. NelsonE, MerrillD, SweetC, et al. Efficacy and safety of oral MK-954 (Du753), an angiotensin receptor antagonist, in essential hypertension.J Hypertens 1991;9(Suppl 6): S468-S469.

    Google Scholar 

  12. SamaniNJ, SwalesJD, BrammarWJ. Expression of the renin gene in extrarenal tissues of the rat.Biochem J 1988; 253:907–910.

    PubMed  CAS  Google Scholar 

  13. ClozelJ-P, FischliW, MénardJ. Effects of the blockade of the renin angiotensin system in cyclosporin-induced hypertension.J Hypertens 1993;11:75–81.

    Article  PubMed  CAS  Google Scholar 

  14. KiowskiW, LinderL, KleinbloesemC, et al. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition.Circulation 1992;85:1–8.

    PubMed  CAS  Google Scholar 

  15. AzizíM, GuyeneTT, ChatellierG, MénardJ. Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension.J Hypertens 1994;12:419–427.

    Article  PubMed  Google Scholar 

  16. van denMeirackerAH, AdmiraalPJJ, DerkxFHM, et al. Comparison of blood pressure and angiotensin responses to the renin inhibitor Ro 42-5892 and the angiotensin converting enzyme inhibitor enalapril in essential hypertension.J Hypertens 1993;11:831–838.

    Article  PubMed  Google Scholar 

  17. MénardJ, BogerRS, MoyseDM, GuyeneTT, GlassmanHN, KleinertHD. Dose-dependent effects of the renin inhibitor zankiren HCl after a single oral dose in midly sodium-depleted normotensive subjects.Circulation 1995;91: 330–338.

    PubMed  Google Scholar 

  18. WeberMA, NeutelJM, EssingerI, GlassmanHN, BogerRS, LutherR. Assessment of renin dependency of hypertension with a dipeptide renin inhibitor.Circulation 1990; 81:1768–1774.

    PubMed  CAS  Google Scholar 

  19. OgiharaT, NaganoM, HigakiJ, HigashimoriK, MasuoK, MikamiH. Antihypertensive efficacy of FK906, a novel human renin inhibitor.Clin Ther 1993;15:539–548.

    PubMed  CAS  Google Scholar 

  20. BogerRS, GlassmannHN, CavanaughJH, et al. Prolonged duration of blood pressure response to enalkiren, the novel dipeptide renin inhibitor, in essential hypertension.Hypertension 1990;15:835–840.

    PubMed  CAS  Google Scholar 

  21. KiowskiW, BeermannJ, RickenbacherP, et al. Angiotensinergic versus nonangiotensinergic hemodynamic effects of converting enzyme inhibition in patients with chronic heart failure. Assessment by acute renin and converting enzyme inhibition.Circulation. 1994;90:2748–2756.

    PubMed  CAS  Google Scholar 

  22. NeubergGW, PennJ, KukinML, et al. Hemodynamic effects of enalkiren, a direct inhibitor of plasma renin, in patients with chronic heart failure (abst).Clin Res 1990;38: 253.

    Google Scholar 

  23. AndohTF, NagotomiI, HoriraiH, et al. Comparative effects of FK 906, an orally active renin inhibitor and captopril on blood pressure and renal hemodynamics in cynomolgus monkeys.J Am Soc Nephrol 1992;3:557.

    Google Scholar 

  24. ElamraniA, MénardJ, GonzalesMF, MichelJB. Effects of blocking the angiotensin-II receptor, converting enzyme, and renin activity on the renal hemodynamics of normotensive guinea pigs.J Cardiovasc Pharmacol 1993;22:231–239.

    Article  CAS  Google Scholar 

  25. HollenbergNK, FisherNDL. Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting inhibition the last word?Hypertension 1995; 26:602–609.

    PubMed  CAS  Google Scholar 

  26. National High Blood Pressure Education Program. National High Blood Pressure Education Program Working Group Report on Hypertension and Chronic Renal Failure.Arch Intern Med 1991;151:1280–1287.

    Article  Google Scholar 

  27. BjorckST, MulecH, JohnsenSA, et al. Renal protective effect of enalapril in diabetic nephropathy.Br Med J 1992; 304:339–343.

    Article  CAS  Google Scholar 

  28. LewisEJ, HunsickerLG, RohdeRP. The effects of angiotensin-converting-enzyme inhibition on diabetic nephropathy.N Engl J Med 1993;329:1456–1462.

    Article  PubMed  CAS  Google Scholar 

  29. KamperAL, StrandgaardS, LeyssacPP. Effect of enalapril on the progression of chronic renal failure. A randomized controlled trial.Am J Hypertens 1992;5:423–430.

    PubMed  CAS  Google Scholar 

  30. HannedoucheT, LandaisP, GodfarbB, et al. Randomized controlled trial of enalapril and beta-blockers in non-diabetic chronic renal failure.Br Med J 1994;309:833–837.

    CAS  Google Scholar 

  31. RitzE. Are antihypertensive drugs similar in protecting the kidney?Am J Hypertens 1995;8(Suppl):53–58.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Pharmaceutical Division, CIBA Geigy, Ltd., CH 4002, Basle, Switzerland

    Jeanette M. Wood & Philippe Close

Authors
  1. Jeanette M. Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Philippe Close
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wood, J.M., Close, P. Renin Inhibitors: Cardiovascular drugs of the future?. Cardiovasc Drug Ther 10, 309–312 (1996). https://doi.org/10.1007/BF02627954

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02627954

Key Words

search

Navigation